Boston Scientific wrote a $1.5 billion check on Monday to re-enter a market it exited twice. The company invested in MiRus LLC for a 34% equity stake and an exclusive option to acquire the SIEGEL balloon-expandable TAVR system—the first nickel-free TAVR valve in clinical development—for an additional $3 billion if milestones are met. Announced the same day as a $2 billion accelerated share repurchase, the moves signal that BSX is deploying capital aggressively to rebuild its structural heart franchise after discontinuing two prior TAVR programs. Elsewhere, the FDA and the medtech industry are nearing a MDUFA VI deal that should cut device review fees and hire more than 500 additional reviewers. Welcome to Issue #23.
Top Stories
Story 01
Boston Scientific announced on May 18, 2026 that it has invested $1.5 billion in MiRus LLC, a privately held company developing biomaterials and implants for cardiovascular and orthopedic diseases, in exchange for an approximately 34% equity stake. The investment includes an exclusive option to acquire MiRus’s TAVR business for an additional $3 billion in cash payments, contingent on MiRus meeting specified clinical and regulatory milestones with its SIEGEL Balloon-Expandable Transcatheter Aortic Valve Replacement system. MiRus recently initiated the STAR pivotal trial evaluating the SIEGEL valve in up to 1,025 patients with severe, symptomatic aortic stenosis across low-, intermediate-, and high-risk surgical cohorts. BSX stock rose approximately 5.9% on the day of the announcement. (Source: Boston Scientific, May 18, 2026)
The investment is BSX’s third attempt at the TAVR market after discontinuing its Lotus valve program in 2021 and halting sales of the ACURATE neo2 and ACURATE Prime systems in May 2025. MiRus is developing the SIEGEL valve using a proprietary rhenium alloy—making it the first nickel-free, balloon-expandable TAVR valve in development. Boston Scientific simultaneously announced a $2 billion accelerated share repurchase agreement with JPMorgan Chase as part of its previously authorized $5 billion buyback program. Taken together, the two announcements represent $3.5 billion in capital deployment in a single day, the largest single-day capital allocation event in BSX’s recent history.
Why It Matters: BSX exited the TAVR market twice when its own programs failed to compete with Edwards SAPIEN and Medtronic Evolut. Rather than build a third internal program—which would take 7–10 years and carry significant R&D risk—it acquired an equity stake and a call option. That structure gives BSX strategic exposure to MiRus’s upside without committing to full ownership until the clinical and regulatory milestones de-risk the asset. If the SIEGEL valve clears the STAR pivotal trial, BSX can exercise the option and enter the $7 billion global TAVR market with a genuinely differentiated product. If it does not, the $1.5 billion investment caps the loss.
Strategic Investment
Structural Heart
TAVR
Why This Matters for Builders
BSX failed twice in TAVR with its own organically developed products. Instead of a third internal program, it structured this as a minority equity investment plus a call option—a product option, not a company acquisition. That structure is the key insight. When you have failed twice at a market and still need to be there, the right move is not to build again from scratch. It is to buy a call option on the best emerging entrant at a price that reflects current clinical risk, not future market potential. The $1.5B stake is expensive, but it is far cheaper than a full $4.5B acquisition of an unproven clinical asset. Builders note: option-based M&A structures are increasingly how large-cap medtech manages R&D risk in high-stakes markets where organic success rates are low.
Story 02
The FDA and the medtech industry are nearing a final agreement on MDUFA VI, the next five-year cycle of medical device user fee funding that sets staffing and review timeline commitments through 2028 and beyond. According to FDA meeting minutes released May 14, 2026, the new agreement includes marginal increases in staffing and operational expenses above the MDUFA V baseline, with most companies expected to see lower fees in fiscal year 2028 due to changes in the statutory fee structure. The FDA said MDUFA VI includes a commitment to hire “substantial numbers” of medical device review staff, continuing the 500+ headcount expansion initiated under MDUFA V. The fee structure changes include decreases to submission fees and domestic registration fees. (Source: MedTech Dive, May 14, 2026)
MDUFA negotiations set the financial and operational terms under which the FDA’s Center for Devices and Radiological Health (CDRH) operates for a five-year cycle. Under the current MDUFA V agreement, the medtech industry agreed to higher fees in exchange for CDRH hiring more than 500 reviewers—an expansion designed to reduce 510(k) and PMA review timelines. The FDA is taking an “America First” approach to the new negotiations, according to an HHS spokesperson, focusing on domestic medical device innovation, supply chain resilience, and access to safe and effective technologies for U.S. patients.
Why It Matters: Lower fees and more reviewers is the combination the medtech industry has been asking for since MDUFA IV. The practical effect: faster 510(k) and PMA review timelines and lower cost of submission, which disproportionately benefits smaller companies and startups with limited capital to absorb multi-year review cycles. If MDUFA VI delivers on both promises, the FDA access bottleneck that has driven many device companies to prioritize CE Mark over U.S. clearance becomes less severe. That is a structural tailwind for the U.S. device market.
FDA / Regulatory
MDUFA VI
Industry Shift
Story 03
Medtronic led a $100 million investment round in Pulnovo Medical, a company developing the PADN (Pulmonary Artery Denervation) system for the treatment of pulmonary hypertension. Alongside the investment, Medtronic entered a commercial agreement with Pulnovo for the PADN device. Pulnovo recently filed to enroll approximately 750 pulmonary hypertension patients in a placebo-controlled pivotal trial of the PADN system at the Icahn School of Medicine at Mount Sinai, with regulatory clearance to run two clinical trials in the U.S. The PADN device uses radiofrequency energy to disrupt the sympathetic nerve network at the pulmonary artery bifurcation—a novel mechanism for reducing pulmonary arterial pressure. The device is already commercially available in China and Europe. (Source: MedTech Dive, May 2026)
Pulmonary hypertension is a progressive, life-threatening disease affecting the arteries of the lungs and the right side of the heart. Current pharmacological treatments slow progression but do not address the underlying autonomic nervous system dysregulation that drives elevated pulmonary arterial pressure. Pulnovo’s PADN system targets this mechanism directly—a catheter-based intervention that ablates the sympathetic nerves surrounding the pulmonary artery bifurcation to reduce vascular resistance. Early data from registries in China and Europe have shown meaningful reductions in pulmonary arterial pressure and improvements in functional capacity.
Why It Matters: Medtronic is building a position in pulmonary hypertension ahead of a pivotal U.S. trial that could create a new procedural category. The commercial agreement alongside the investment gives Medtronic distribution leverage if the device clears FDA—a structure that looks like the CathWorks playbook: invest early, sign a commercial agreement, close the acquisition after clinical proof-of-concept. Pulmonary hypertension represents a large unmet need with limited device-based treatment options. If PADN proves efficacy in the U.S. pivotal trial, Medtronic holds the distribution rights to the first interventional treatment in a category dominated by pharmacotherapy.
Cardiology
Clinical Trial
Strategic Investment
Market Movers
| Ticker | Company | Price | Wk Change |
|---|
| ISRG | Intuitive Surgical | $463.50 | ▲ 0.3% |
| SYK | Stryker | $301.40 | ▲ 0.4% |
| BSX ★ | Boston Scientific | $55.80 | ▲ 5.9% |
| JNJ | Johnson & Johnson | $226.10 | ▲ 0.3% |
| ABT | Abbott | $92.30 | ▲ 0.5% |
| GEHC | GE HealthCare | $64.20 | ▲ 0.6% |
| EW | Edwards Lifesciences | $86.80 | ▲ 0.3% |
| BDX | BD (Becton Dickinson) | $150.90 | ▲ 0.5% |
| MDT | Medtronic | $78.10 | ▲ 0.8% |
| STE | Steris | $243.60 | ▼ 0.2% |
★ Biggest Mover: BSX surged 5.9% on Monday after announcing a $1.5B investment in MiRus LLC for 34% equity and an exclusive TAVR option, combined with a $2B accelerated share repurchase. The structural heart re-entry narrative and buyback signal drove the outperformance. MDT gained 0.8% on Pulnovo investment news. Sorted by stock price, highest to lowest. Prices reflect approximate close, week of May 19–23, 2026. For illustrative purposes only.
Deep Dive
The Option-Based M&A Playbook: How Large-Cap MedTech Manages R&D Risk in High-Stakes Markets
Boston Scientific’s MiRus investment is not a traditional acquisition. It is a structured option—and that structure tells you more about the current state of medtech capital allocation than any single deal has in years.
- The failure tax is real. BSX failed twice in TAVR—first with Lotus, then with ACURATE. A third internal program would carry that institutional scar tissue: the organizational memory of two failed attempts, the R&D spend to get back to clinical readiness, and the 7–10 year timeline before U.S. commercialization. The $1.5 billion option buys BSX exposure to MiRus’s already-running pivotal trial without absorbing the failure tax. The clinical risk belongs to MiRus until the milestones are met.
- Options preserve capital optionality. BSX pays $1.5B now for a 34% stake and a call option. If the SIEGEL valve fails the STAR trial, BSX loses the $1.5B but does not owe the additional $3B. That asymmetric structure—bounded downside, large upside—is exactly how a capital-efficient acquirer manages uncertainty in a high-risk clinical market. Compare this to a full $4.5B acquisition of a pre-commercial asset: the full $4.5B is at risk regardless of whether the trial succeeds.
- The nickel-free differentiation is non-trivial. The SIEGEL valve’s rhenium alloy eliminates nickel, a material that triggers hypersensitivity reactions in a subset of TAVR patients. If the pivotal trial data confirms clinical non-inferiority to Edwards and Medtronic’s established platforms, the nickel-free profile gives BSX a defensible label claim in a market where competitive differentiation is increasingly difficult to achieve through efficacy alone.
The option-based M&A structure is becoming the preferred playbook for large-cap medtech in markets where internal R&D has failed and full acquisitions carry excessive clinical risk. Expect to see more of these deals: a minority equity investment, a commercial agreement, and an exclusive call option triggered by clinical or regulatory milestones. It is cheaper than acquisition, more committed than a partnership, and more defensible than organic development in markets that have already been proven. BSX is the first mover on this structure in TAVR. It will not be the last.
The Builder’s Take
BSX Didn’t Buy a Company. It Bought the Right to Compete Again.
Two failed TAVR programs. A $1.5 billion check. An option that could cost $3 billion more. This is not capital discipline—it is desperation rationalized as strategy. And that is fine, because the alternative is worse: watching Edwards and Medtronic own the $7 billion TAVR market indefinitely while BSX’s structural heart franchise atrophies after two high-profile exits.
The builder lesson here is counterintuitive: sometimes the most rational move is to pay for a second chance at a market you already failed in twice. The key is the structure. BSX did not pay $4.5B for MiRus outright—it paid $1.5B for the right to acquire the TAVR business if the clinical proof materializes. That is the option premium for clinical uncertainty. If you are building in a high-risk clinical category, understanding how to structure partnerships and options—not just outright sales—is increasingly the skill that determines whether you get acquired or get passed over.
⏳ That’s your 5-minute briefing. Below: extras if you want to go deeper.
Fun Fact
💡 Fun Fact — The TAVR Revolution
The first transcatheter aortic valve replacement in a human was performed in 2002. The global TAVR market now exceeds $7 billion annually.
Trivia
MedTech Trivia
What material makes the MiRus SIEGEL valve unique among balloon-expandable TAVR systems currently in clinical development, and why does that material property matter clinically?
If you’re building, hiring, or investing in MedTech, reply and tell me what you’re seeing. I read every response.
